CYCC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 23.97%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $5,838,864.60

Cyclacel Pharmaceuticals Insider Trading History Chart

Cyclacel Pharmaceuticals Share Price & Price History

^$0.23

▼ -0.0152 (-6.20%)

As of 04/3/2025 05:00 PM ET

Days: 30 | 90 | 365

Cyclacel Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/26/2025	David E. Lazar	CEO	Sell	194,628,820	$0.03	$5,838,864.60
12/21/2023	Paul Mcbarron	Insider	Buy	1,886	$3.31	$6,242.66	33,378
12/21/2023	Spiro George Rombotis	CEO	Buy	6,070	$3.31	$20,091.70	68,658

SEC Filings (Institutional Ownership Changes) for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

23.58% of Cyclacel Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cyclacel Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2024	Armistice Capital LLC	134,000	$0.22M	0.0%	N/A	9.178%
5/10/2024	Acadian Asset Management LLC	14,285	$29K	0.0%	-41.0%	1.084%
11/1/2022	Kestra Advisory Services LLC	23,000	$34K	0.0%	N/A	0.183%
10/25/2022	Raymond James Financial Services Advisors Inc.	20,806	$30K	0.0%	-32.5%	0.166%
10/18/2022	McIlrath & Eck LLC	26,342	$38K	0.0%	N/A	0.210%
8/15/2022	Sio Capital Management LLC	454,355	$0.49M	0.2%	+7.5%	4.546%
2/10/2022	Acadian Asset Management LLC	23,242	$89K	0.0%	N/A	0.233%
11/16/2021	Two Sigma Advisers LP	121,500	$0.64M	0.0%	+929.7%	1.316%
11/15/2021	Pura Vida Investments LLC	105,141	$0.55M	0.0%	-33.2%	1.139%
11/15/2021	Tri Locum Partners LP	522,943	$2.76M	1.1%	+66.9%	5.663%
11/12/2021	Affinity Asset Advisors LLC	400,000	$2.11M	0.5%	+5.3%	4.332%
11/2/2021	Raymond James Financial Services Advisors Inc.	10,006	$53K	0.0%	-83.3%	0.108%
10/15/2021	NEXT Financial Group Inc	14,752	$77K	0.0%	+70.0%	0.160%
8/18/2021	Ikarian Capital LLC	100,000	$0.59M	0.0%	-66.7%	1.083%
8/17/2021	Boothbay Fund Management LLC	10,545	$62K	0.0%	-66.7%	0.114%
8/17/2021	Citadel Advisors LLC	250,797	$1.49M	0.0%	-14.7%	2.716%
8/16/2021	Tri Locum Partners LP	313,331	$1.86M	0.6%	+6.8%	3.393%
8/16/2021	Schonfeld Strategic Advisors LLC	102,525	$0.61M	0.0%	-25.0%	1.110%
8/16/2021	Maven Securities LTD	234,500	$1.43M	0.1%	-6.2%	2.540%
8/13/2021	Northern Trust Corp	14,957	$89K	0.0%	N/A	0.162%
8/13/2021	Geode Capital Management LLC	50,860	$0.30M	0.0%	+143.3%	0.551%
8/13/2021	Vanguard Group Inc.	327,658	$1.94M	0.0%	+9.2%	3.548%
7/31/2021	NEXT Financial Group Inc	8,680	$51K	0.0%	N/A	0.094%
5/19/2021	Virtu Financial LLC	13,108	$93K	0.0%	+27.3%	0.142%
5/19/2021	Squarepoint Ops LLC	23,836	$0.17M	0.0%	N/A	0.258%
5/18/2021	Point72 Asset Management L.P.	230,000	$1.64M	0.0%	N/A	2.491%
5/18/2021	Verition Fund Management LLC	116,674	$0.83M	0.0%	N/A	1.264%
5/18/2021	Morgan Stanley	100,000	$0.71M	0.0%	-13.0%	1.083%
5/18/2021	Citadel Advisors LLC	293,867	$2.09M	0.0%	N/A	3.182%
5/18/2021	Silverarc Capital Management LLC	250,000	$1.78M	1.0%	N/A	2.707%
5/17/2021	Schonfeld Strategic Advisors LLC	136,725	$0.97M	0.0%	N/A	1.481%
5/17/2021	Sphera Funds Management LTD.	508,322	$3.61M	0.3%	N/A	5.505%
5/17/2021	Ikarian Capital LLC	300,000	$2.13M	0.1%	-23.4%	3.249%
5/12/2021	Geode Capital Management LLC	20,904	$0.15M	0.0%	N/A	0.226%
5/12/2021	Pura Vida Investments LLC	273,958	$1.95M	0.1%	-42.3%	2.967%
5/11/2021	Acadian Asset Management LLC	34,057	$0.24M	0.0%	N/A	0.369%
4/12/2021	Valeo Financial Advisors LLC	4,500	$32K	0.0%	N/A	0.063%
2/24/2021	Virtu Financial LLC	10,293	$80K	0.0%	N/A	0.212%
2/12/2021	Raymond James Financial Services Advisors Inc.	57,006	$0.45M	0.0%	+24.6%	1.172%

Data available starting January 2016

See Full Table

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Today's Range

Now: $0.23

$0.23

$0.25

50 Day Range

MA: $0.32

$0.23

$0.38

52 Week Range

Now: $0.23

$0.22

$4.00

Volume

139,779 shs

Average Volume

1,203,733 shs

Market Capitalization

$1.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Who are the company insiders with the largest holdings of Cyclacel Pharmaceuticals?: Cyclacel Pharmaceuticals' top insider investors include:
Spiro George Rombotis (CEO)
Paul Mcbarron (Insider)
David E Lazar (CEO)
Learn More about top insider investors at Cyclacel Pharmaceuticals.